Circadian disruption is closely associated with Alzheimer's disease pathology and therapeutic response, supporting chronotherapeutic strategies.
This narrative review synthesizes evidence that circadian dysfunction contributes to Alzheimer's disease pathogenesis through interactions between core clock genes and neurodegenerative cascades involving oxidative stress, neuroinflammation, glial reactivity, and proteostasis. Emerging evidence suggests distinct circadian patterns in AD-relevant biomarkers, including melatonin, cortisol, orexin, core body temperature, blood-brain barrier permeability, and glial marker oscillations, which may have diagnostic and prognostic relevance.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Circadian disruption is closely associated with Alzheimer's disease pathology and therapeutic response, supporting chronotherapeutic strategies. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Circadian disruption is closely associated with Alzheimer's disease pathology and therapeutic response, supporting chronotherapeutic strategies.
This conclusion is most relevant to: Alzheimer's disease patients (human studies) and mechanistic models (animal/cellular studies).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Circadian rhythms and chronotherapy in Alzheimer's disease: Mechanisms and therapeutic implications. (Neuroprotection (Chichester, England), 2026) — This narrative review synthesizes evidence that circadian dysfunction contributes to Alzheimer's disease pathogenesis through interactions between core clock genes and neurodegenerative cascades involving oxidative stress, neuroinflammation, glial reactivity, and proteostasis. Emerging evidence suggests distinct circadian patterns in AD-relevant biomarkers, including melatonin, cortisol, orexin, core body temperature, blood-brain barrier permeability, and glial marker oscillations, which may have diagnostic and prognostic relevance.
How It Works
The proposed biological pathway:
- ▸Circadian disruption alters core clock gene expression (e.g., BMAL1, PER2)
- ▸Clock gene dysregulation affects downstream pathways: BMAL1-SIRT1, NF-κB-NLRP3, PER2-antioxidant signaling
- ▸These pathways promote oxidative stress, neuroinflammation, glial reactivity, and proteostasis failure
- ▸Result: Compromised neuronal resilience and worsened AD-related pathology
Who Might Benefit
Evidence fit by population:
- ▸Alzheimer's disease patients (human studies) and mechanistic models (animal/cellular studies)
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸This is a narrative review, not a systematic review or meta-analysis, so conclusions are qualitative
- ▸Large-scale clinical trials on chronotherapeutic strategies in AD are lacking
- ▸The review does not provide specific effect sizes or quantitative data from individual studies
Frequently Asked Questions
What is chronotherapy in Alzheimer's disease?▼
Chronotherapy involves timing treatments (e.g., melatonin agonists, light therapy, time-restricted feeding) to align with circadian rhythms, potentially improving outcomes in Alzheimer's disease by targeting circadian disruption.
How does circadian disruption affect Alzheimer's pathology?▼
Circadian disruption alters clock genes like BMAL1 and PER2, which interact with pathways involving oxidative stress, neuroinflammation, and proteostasis, worsening neuronal resilience and AD pathology.
What biomarkers show circadian patterns in Alzheimer's?▼
Biomarkers such as melatonin, cortisol, orexin, core body temperature, blood-brain barrier permeability, and glial marker oscillations exhibit distinct circadian patterns that may aid diagnosis and prognosis.
Are there clinical trials on chronotherapy for Alzheimer's?▼
The review highlights that large-scale clinical trials on chronotherapeutic strategies in AD are still lacking, though emerging evidence supports their potential.
References
- 1.Singh B, Pigazzani F, Manfredini R. “Circadian rhythms and chronotherapy in Alzheimer's disease: Mechanisms and therapeutic implications..” Neuroprotection (Chichester, England), 2026. PMID: 42499341 DOI: 10.1002/nep3.70046